BMRN Earnings
Latest Revenue989.7M
Latest Net Income44.8M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.23 | 989.7M | 44.8M | +19.9% | -81.6% |
| Q1 2026 | $0.55 | 766.2M | 105.5M | +2.8% | -43.3% |
| Q4 2025 | -$0.24 | 874.6M | -46573000 | +17.0% | -136.4% |
| Q3 2025 | -$0.16 | 776.1M | -30744000 | +4.1% | -128.6% |
| Q2 2025 | $1.25 | 825.4M | 240.5M | +15.9% | +123.2% |
| Q1 2025 | $0.97 | 745.1M | 185.7M | +14.8% | +106.4% |
| Q4 2024 | $0.66 | 747.3M | 124.9M | +15.6% | +500.0% |
| Q3 2024 | $0.56 | 745.7M | 106.1M | +28.3% | +166.7% |
| Q2 2024 | $0.56 | 712.0M | 107.2M | — | — |
| Q1 2024 | $0.47 | 648.8M | 88.7M | — | — |
| Q4 2023 | $0.11 | 646.2M | 20.4M | — | — |
| Q3 2023 | $0.21 | 581.3M | 40.4M | — | — |
BioMarin Pharmaceuticals (BMRN) — Earnings